
-
Fate Therapeutics NasdaqGM:FATE Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Location: 12278 Scripps Summit Drive, San Diego, CA, 92131, United States | Website: https://www.fatetherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-5.777M
Cash
240.4M
Avg Qtr Burn
-30.83M
Short % of Float
13.94%
Insider Ownership
1.74%
Institutional Own.
94.28%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FT825/ONO-8250 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
FT819 (CAR-19, TCR-KO) Details Systemic lupus erythematosus | Phase 1 Data readout | |
FT819 (CAR-19, TCR-KO) Details B-cell lymphoma, Solid tumor/s, Cancer, Chronic lymphocytic leukemia | Phase 1 Update | |
FT576 (iNK hnCD16) + daratumumab Details Cancer, Multiple myeloma | Phase 1 Update | |
FT522 (CAR NK Cell Program) Details Cancer, B-cell lymphoma | Phase 1 Update | |
FT538 (hnCD16 + IL-15RF + CD38KO) Details Multiple myeloma, Cancer | Failed Discontinued | |
FT516 (NK cells - engineered CD16 FcR) Details Solid tumor/s, B-cell lymphoma, Diffuse large B cell lymphoma | Failed Discontinued | |
FT596 (CAR19, hnCD16, IL-15RF) + R-CHOP Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia | Failed Discontinued | |
FT516 (NK cells - engineered CD16 FcR) + rituximab Details Solid tumor/s, B-cell lymphoma, Cancer | Failed Discontinued | |
ProTmune (CD34+) Details Acute graft-versus host disease | Failed Discontinued | |
FT500 (PD1/PD-L1) Details Solid tumor/s, Cancer | Failed Discontinued | |
FT596 (CAR19, hnCD16, IL-15RF) + rituximab Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia | Failed Discontinued |